Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Get Free Report) has received an average recommendation of “Buy” from the six analysts that are covering the firm, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have covered the stock in the last year is $29.50.
Several research firms have issued reports on CPRX. HC Wainwright increased their target price on Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. Truist Financial upped their price target on Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, Citigroup raised their price objective on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a research report on Friday, August 9th.
Get Our Latest Research Report on CPRX
Insider Buying and Selling
Institutional Trading of Catalyst Pharmaceuticals
Hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of Catalyst Pharmaceuticals by 12.1% in the 1st quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company’s stock worth $127,212,000 after acquiring an additional 860,244 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Catalyst Pharmaceuticals by 9.6% in the second quarter. Dimensional Fund Advisors LP now owns 3,000,756 shares of the biopharmaceutical company’s stock worth $46,479,000 after purchasing an additional 263,099 shares during the last quarter. Pacer Advisors Inc. boosted its position in Catalyst Pharmaceuticals by 130,918.8% during the second quarter. Pacer Advisors Inc. now owns 2,967,575 shares of the biopharmaceutical company’s stock valued at $45,968,000 after buying an additional 2,965,310 shares during the period. Janus Henderson Group PLC grew its stake in shares of Catalyst Pharmaceuticals by 139.5% during the first quarter. Janus Henderson Group PLC now owns 2,726,388 shares of the biopharmaceutical company’s stock valued at $43,445,000 after buying an additional 1,587,794 shares during the last quarter. Finally, Renaissance Technologies LLC increased its holdings in shares of Catalyst Pharmaceuticals by 15.2% in the second quarter. Renaissance Technologies LLC now owns 2,175,727 shares of the biopharmaceutical company’s stock worth $33,702,000 after buying an additional 287,300 shares during the period. Hedge funds and other institutional investors own 79.22% of the company’s stock.
Catalyst Pharmaceuticals Stock Performance
Shares of CPRX opened at $21.16 on Friday. Catalyst Pharmaceuticals has a fifty-two week low of $11.89 and a fifty-two week high of $21.85. The business has a 50-day moving average of $20.08 and a 200 day moving average of $17.32. The firm has a market cap of $2.50 billion, a P/E ratio of 39.19, a price-to-earnings-growth ratio of 3.18 and a beta of 0.76.
Catalyst Pharmaceuticals (NASDAQ:CPRX – Get Free Report) last posted its earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.13. The firm had revenue of $122.71 million during the quarter, compared to the consensus estimate of $111.76 million. Catalyst Pharmaceuticals had a net margin of 15.69% and a return on equity of 27.77%. As a group, research analysts predict that Catalyst Pharmaceuticals will post 1.82 earnings per share for the current fiscal year.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.
Further Reading
- Five stocks we like better than Catalyst Pharmaceuticals
- How to Invest in Insurance Companies: A Guide
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- Insider Buying Explained: What Investors Need to Know
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- What is a Dividend King?
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.